source
- Novo Nordisk lifts 2026 guidance as Wegovy sales surge in Q1Novo Nordisk reported its first‑quarter results, noting that sales and operating profit are expected to decline less than previously forecast. The company said adjusted sales fell between 4% and 1…
- Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancerThe DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…